2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was approximately CNY 10.87 billion, representing a year-on-year increase of 4.68% compared to CNY 10.38 billion in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was approximately CNY 986.97 million, a significant increase of 116.17% from CNY 462.51 million in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 919.32 million, reflecting a year-on-year growth of 14.78%[5] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.37, up 105.56% from CNY 0.18 in the same quarter last year[5] - The total comprehensive income for the first quarter of 2023 was CNY 930,767,631.49, compared to CNY 365,586,120.33 in the same period of 2022, representing a significant increase[28] - The net profit for Q1 2023 reached RMB 1.11 billion, up 75.6% compared to RMB 634.16 million in Q1 2022[27] Assets and Liabilities - The company's total assets at the end of Q1 2023 were approximately CNY 107.38 billion, a slight increase of 0.20% from CNY 107.16 billion at the end of the previous year[6] - Shareholders' equity attributable to the company was approximately CNY 45.39 billion, an increase of 1.82% from CNY 44.58 billion at the end of the previous year[6] - The company's total liabilities decreased to RMB 52.33 billion as of March 31, 2023, from RMB 53.05 billion at the end of 2022[26] - The company's total liabilities decreased to CNY 14,007,704,743.99 as of March 31, 2023, from CNY 15,300,001,896.39 at the end of 2022[33] Cash Flow - The net cash flow from operating activities for Q1 2023 was approximately CNY 873.24 million, a slight increase of 2.06% from CNY 865.59 million in the same period last year[5] - The company reported a net cash flow from operating activities of RMB 873 million, up 2.06% year-on-year[18] - The net cash flow from operating activities for Q1 2023 was CNY 371,357,088.18, a significant improvement from a negative CNY 464,722,394.46 in Q1 2022[36] - The cash inflow from financing activities for Q1 2023 was CNY 281,971,154.45, down from CNY 1,553,311,047.09 in Q1 2022[31] Research and Development - Research and development expenses for Q1 2023 were RMB 968.87 million, an increase of 19.6% from RMB 809.68 million in Q1 2022[27] - The company’s innovative drug FS-1502 for HER2-positive breast cancer has entered Phase III clinical trials in China[20] - The company launched its first innovative drug, Hanszhuang (Sruvelizumab injection), for extensive-stage small cell lung cancer, marking it as the first PD-1 monoclonal antibody approved for this indication globally[19] Product Pipeline and Market Expansion - The increase in revenue and net profit was primarily driven by the sales growth of new products such as Hanshu (SruLi monoclonal antibody injection) and Hanquyou (trastuzumab injection)[6] - The company’s product pipeline includes multiple innovative drugs entering critical clinical and approval stages, with the first domestic biosimilar drug, Hanquyou (injection trastuzumab), having its BLA accepted by the FDA[20] - The company is expanding its global footprint and enhancing its product pipeline through both independent R&D and external collaborations[17] - The company plans to enhance product accessibility in emerging markets in Asia and Africa through a licensing agreement with Boston Oncology[22] Shareholder Information - The company’s major shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 33.14% of the shares, with 383.88 million shares pledged[14] Acquisitions and Collaborations - Sisram signed an agreement to acquire the "Photon" brand and channels, aiming for direct sales of energy source medical beauty equipment in the Chinese market[22] - Gland Pharma completed the acquisition of European CDMO company Cenexi, enhancing its strategic presence in the European market[22]